1. Falagas ME, Voidonikola PT, Angelousi AG. 2007; Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents. 30:477–86. DOI:
10.1016/j.ijantimicag.2007.07.010. PMID:
17913470.
Article
2. Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, et al. 2010; Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 49:1815–27. DOI:
10.1093/rheumatology/keq183. PMID:
20591834. PMCID:
PMC2936949.
Article
3. Bosch X, Guilabert A, Pallarés L, Cerveral R, Ramos-Casals M, Bové A, et al. 2006; Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 15:584–9. DOI:
10.1177/0961203306071919. PMID:
17080913.
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. 2002; Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 46:2294–300. DOI:
10.1002/art.10529. PMID:
12355476.
Article
7. Glück T, Müller-Ladner U. 2008; Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 46:1459–65. DOI:
10.1086/587063. PMID:
18419456.
8. Hmamouchi I, Winthrop K, Launay O, Dougados M. 2015; Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 33:1446–52. DOI:
10.1016/j.vaccine.2015.01.065. PMID:
25659279.
Article
9. Kim SY, Choi MY, Shin SS, Ji SM, Park JJ, Yoo JH, et al. 2015. Handbook for clinical practice guideline developer version 1.0. National Entertainment Collectibles Association;Seoul: p. 1–428.
10. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. 2012; AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 7:e33536. DOI:
10.1371/journal.pone.0033536. PMID:
22470453. PMCID:
PMC3314666.
Article
11. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. 2014; Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 13:600–13. DOI:
10.1016/S1474-4422(14)70075-4.
Article
12. Mantadakis E, Farmaki E, Buchanan GR. 2010; Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr. 156:623–8. DOI:
10.1016/j.jpeds.2009.10.015. PMID:
20097358.
Article
13. Andrews N, Stowe J, Miller E, Svanström H, Johansen K, Bonhoeffer J, et al. VAESCO consortium. 2012; A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine. 30:3042–6. DOI:
10.1016/j.vaccine.2011.06.009. PMID:
21699947.
Article
14. Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. 2001; Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 84:227–9. DOI:
10.1136/adc.84.3.227. PMID:
11207170. PMCID:
PMC1718684.
17. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. 2013; Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 47:1–16. DOI:
10.1016/j.jaut.2013.10.004. PMID:
24238833.
Article
18. Louie JS, Nies KM, Shoji KT, Fraback RC, Abrass C, Border W, et al. 1978; Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med. 88:790–2. DOI:
10.7326/0003-4819-88-6-790. PMID:
307356.
Article
19. Zycinska K, Romanowska M, Nowak I, Rybicka K, Wardyn KA, Brydak LB. 2007; Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis. J Physiol Pharmacol. 58 Suppl 5(Pt 2):819–28.
20. Ristow SC, Douglas RG Jr, Condemi JJ. 1978; Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med. 88:786–9. DOI:
10.7326/0003-4819-88-6-786. PMID:
666135.
Article
21. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. Infectious Diseases Society of America. 2014; 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 58:309–18. DOI:
10.1093/cid/cit816. PMID:
24421306.
Article
22. Cordeiro I, Duarte AC, Ferreira JF, Gonçalves MJ, Meirinhos T, Rocha TM, et al. 2016; Recommendations for vaccination in adult patients with systemic inflammatory rheumatic diseases from the Portuguese Society of Rheumatology. Acta Reumatol Port. 41:112–30.
23. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. 2011; EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 70:414–22. DOI:
10.1136/ard.2010.137216. PMID:
21131643.
Article
24. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2016; 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68:1–26. DOI:
10.1002/art.39480. PMID:
26545940.
Article
25. Bühler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, et al. 2015; Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 145:w14159. DOI:
10.4414/smw.2015.14159. PMID:
26218860.
Article
26. Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association. 2012; recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol. 39:1583–602. DOI:
10.3899/jrheum.120165. PMID:
22707613.
27. Ledingham J, Deighton C. British Society for Rheumatology Standards, Guidelines and Audit Working Group. 2005; Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford). 44:157–63. DOI:
10.1093/rheumatology/keh464. PMID:
15637039.
28. Pham T, Fautrel B, Gottenberg JE, Goupille P, Hachulla E, Masson C, et al. Rheumatic Diseases & Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Société Française de Rhumatologie, SFR). 2008; Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine. 75(Suppl 1):S1–99. DOI:
10.1016/S1297-319X(08)73620-0. PMID:
18708020.
29. Pham T, Claudepierre P, Constantin A, de Bandt M, Fautrel B, Gossec L, et al. Club Rhumatismes et Inflammation (CRI). 2010; Tocilizumab: therapy and safety management. Joint Bone Spine. 77(Suppl 1):S3–100. DOI:
10.1016/S1297-319X(10)70001-4. PMID:
20610315.
Article
30. Pham T, Claudepierre P, Constantin A, Fautrel B, Gossec L, Gottenberg JE, et al. 2009; Abatacept therapy and safety management. Joint Bone Spine. 76(Suppl 1):S3–55. DOI:
10.1016/S1297-319X(09)74520-8. PMID:
19560051.
Article
31. Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille P, Hilliquin P, et al. Club Rhumatismes et Inflammation, French Society of Rheumatology. 2005; Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine. 72(Suppl 1):S1–58.
32. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. 2006; Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 45:106–11. DOI:
10.1093/rheumatology/kei193. PMID:
16287919.
Article
33. Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, et al. 2008; Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine. 26:3528–33. DOI:
10.1016/j.vaccine.2008.04.028. PMID:
18502006.
Article
34. Kaine JL, Kivitz AJ, Birbara C, Luo AY. 2007; Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 34:272–9. PMID:
17304653.
35. Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, et al. 2013; Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 65:476–80. DOI:
10.1002/acr.21838. PMID:
22949223.
Article
36. Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. 2015; Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 74:818–22. DOI:
10.1136/annrheumdis-2013-204427. PMID:
24448345. PMCID:
PMC4392200.
Article
37. Hua C, Barnetche T, Combe B, Morel J. 2014; Effect of methotrexate, anti-tumor necrosis factor
α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 66:1016–26. DOI:
10.1002/acr.22246. PMID:
24339395.
38. Morel J, Czitrom SG, Mallick A, Sellam J, Sibilia J. 2016; Vaccinations in adults with chronic inflammatory joint disease: immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs. Joint Bone Spine. 83:135–41. DOI:
10.1016/j.jbspin.2015.08.008. PMID:
26453106.
Article
39. Brenol CV, Azevedo VF, Bonvehi PE, Coral-Alvarado PX, Granados J, Muñoz-Louis R, et al. 2018; Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America. J Clin Rheumatol. 24:138–47. DOI:
10.1097/RHU.0000000000000624. PMID:
29232324.
Article
41. Staples JE, Gershman M, Fischer M. Centers for Disease Control and Prevention (CDC). 2010; Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 59:1–27.
42. Potter J, Stott DJ, Roberts MA, Elder AG, O'Donnell B, Knight PV, et al. 1997; Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 175:1–6. DOI:
10.1093/infdis/175.1.1. PMID:
8985189. PMCID:
PMC7109672.
Article
43. Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, et al. 2000; Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 355:93–7. DOI:
10.1016/S0140-6736(99)05190-9. PMID:
10675165.
Article
44. Babcock HM, Gemeinhart N, Jones M, Dunagan WC, Woeltje KF. 2010; Mandatory influenza vaccination of health care workers: translating policy to practice. Clin Infect Dis. 50:459–64. DOI:
10.1086/650752. PMID:
20064039.
Article
45. Pearson ML, Bridges CB, Harper SA. Healthcare Infection Control Practices Advisory Committee (HICPAC). Advisory Committee on Immunization Practices (ACIP). 2006; Influenza vaccination of health-care personnel: recommendations of the and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 55:1–16. DOI:
10.1037/e506932006-001.
46. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). 2007; Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 56:1–40.
47. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, et al. 2000; The postmarketing safety profile of varicella vaccine. Vaccine. 19:916–23. DOI:
10.1016/S0264-410X(00)00297-8.
Article
48. Grossberg R, Harpaz R, Rubtcova E, Loparev V, Seward JF, Schmid DS. 2006; Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr. 148:842–4. DOI:
10.1016/j.jpeds.2006.01.038. PMID:
16769402.
Article
49. Nichol KL, Wuorenma J, von Sternberg T. 1998; Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med. 158:1769–76. DOI:
10.1001/archinte.158.16.1769. PMID:
9738606.
Article
50. Blumentals WA, Arreglado A, Napalkov P, Toovey S. 2012; Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 13:158. DOI:
10.1186/1471-2474-13-158. PMID:
22925480. PMCID:
PMC3495205.
Article
51. Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, et al. 1994; Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol. 21:1203–6. PMID:
7966058.
52. Del Porto F, Laganà B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. 2006; Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine. 24:3217–23. DOI:
10.1016/j.vaccine.2006.01.028. PMID:
16466833.
53. Denman EJ, Denman AM, Greenwood BM, Gall D, Heath RB. 1970; Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis. 29:220–31. DOI:
10.1136/ard.29.3.220. PMID:
4194200. PMCID:
PMC1031255.
Article
54. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. 2010; The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 39:442–7. DOI:
10.1016/j.semarthrit.2008.12.002. PMID:
19246078.
Article
55. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. 2006; Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 65:191–4. DOI:
10.1136/ard.2005.036434. PMID:
16014674. PMCID:
PMC1798034.
56. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. 2008; The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 67:713–6. DOI:
10.1136/ard.2007.077552. PMID:
17965123.
57. Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R, et al. 1979; Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA. 242:53–6. DOI:
10.1001/jama.1979.03300010037025. PMID:
312949.
Article
58. Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, et al. 2007; Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 17:531–3. DOI:
10.3109/s10165-007-0632-5. PMID:
18084712.
Article
59. Nii T, Kubota T, Nanki T, Komano Y, Harigai M, Kohsaka H, et al. 2009; Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers. Mod Rheumatol. 19:216–8. DOI:
10.3109/s10165-008-0135-z. PMID:
19015815.
Article
60. Turner-Stokes L, Cambridge G, Corcoran T, Oxford JS, Snaith ML. 1988; In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis. 47:532–5. DOI:
10.1136/ard.47.7.532. PMID:
3261154. PMCID:
PMC1003565.
Article
61. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. 2010; Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 62:75–81. DOI:
10.1002/art.25033. PMID:
20039396.
Article
62. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R. 1978; Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med. 88:729–34. DOI:
10.7326/0003-4819-88-6-729. PMID:
352210.
63. Holvast B, Huckriede A, Kallenberg CG, Bijl M. 2007; Influenza vaccination in systemic lupus erythematosus: safe and protective? Autoimmun Rev. 6:300–5. DOI:
10.1016/j.autrev.2006.09.012. PMID:
17412302.
Article
64. Mercado U, Acosta H, Avendaño L. 2004; Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin. 56:16–20. DOI:
10.7326/0003-4819-88-6-786. PMID:
15144037.
65. Wiesik-Szewczyk E, Romanowska M, Mielnik P, Chwalińska-Sadowska H, Brydak LB, Olesińska M, et al. 2010; Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol. 29:605–13. DOI:
10.1007/s10067-010-1373-y. PMID:
20140692.
Article
67. Borba EF, Saad CG, Pasoto SG, Calich AL, Aikawa NE, Ribeiro AC, et al. 2012; Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology (Oxford). 51:1061–9. DOI:
10.1093/rheumatology/ker427. PMID:
22298793.
Article
68. Brodman R, Gilfillan R, Glass D, Schur PH. 1978; Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med. 88:735–40. DOI:
10.7326/0003-4819-88-6-735. PMID:
307353.
Article
69. Pons VG, Reinertsen JL, Steinberg AD, Dolin R. 1979; Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus. J Med Virol. 4:15–23. DOI:
10.1002/jmv.1890040103. PMID:
231095.
Article
70. Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. 2009; Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum. 60:2438–47. DOI:
10.1002/art.24679. PMID:
19644961.
Article
71. Setti M, Fenoglio D, Ansaldi F, Filaci G, Bacilieri S, Sticchi L, et al. 2009; Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine. 27:3367–72. DOI:
10.1016/j.vaccine.2009.01.078. PMID:
19200840.
Article
72. Holvast A, Stegeman CA, Benne CA, Huckriede A, Wilschut JC, Palache AM, et al. 2009; Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis. 68:873–8. DOI:
10.1136/ard.2008.092924. PMID:
18625625.
Article
73. Pasoto SG, Ribeiro AC, Viana VS, Leon EP, Bueno C, Neto ML, et al. 2013; Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome. Vaccine. 31:1793–8. DOI:
10.1016/j.vaccine.2013.01.057. PMID:
23395584.
Article
74. Kobashigawa T, Nakajima A, Taniguchi A, Inoue E, Tanaka E, Momohara S, et al. 2013; Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol. 42:445–50. DOI:
10.3109/03009742.2013.788733. PMID:
23724971.
Article
78. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. 2002; Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 34:147–53. DOI:
10.1086/338043. PMID:
11740700.
Article
79. Karsh J, Pavlidis N, Schiffman G, Moutsopoulos HM. 1980; Immunization of patients with Sjögren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial. Arthritis Rheum. 23:1294–8. DOI:
10.1002/art.1780231111. PMID:
7004446.
80. Hesselstrand R, Nagel J, Saxne T, Geborek P, Skattum L, Kapetanovic MC. 2018; Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. Rheumatology (Oxford). 57:625–30. DOI:
10.1093/rheumatology/kex471. PMID:
29325173.
Article
81. Nived P, Saxne T, Geborek P, Mandl T, Skattum L, Kapetanovic MC. 2018; Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatment. BMC Rheumatol. 2:12. DOI:
10.1186/s41927-018-0019-6. PMID:
30886963. PMCID:
PMC6390610.
Article
82. Grabar S, Groh M, Bahuaud M, Le Guern V, Costedoat-Chalumeau N, Mathian A, et al. 2017; Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study. Vaccine. 35:4877–85. DOI:
10.1016/j.vaccine.2017.07.094. PMID:
28784280.
Article
83. Nived P, Nagel J, Saxne T, Geborek P, Jönsson G, Skattum L, et al. 2017; Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 35:3639–46. DOI:
10.1016/j.vaccine.2017.05.044. PMID:
28552512.
Article
85. Izumi Y, Akazawa M, Akeda Y, Tohma S, Hirano F, Ideguchi H, et al. 2017; The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial. Arthritis Res Ther. 19:15. DOI:
10.1186/s13075-016-1207-7. PMID:
28122642. PMCID:
PMC5264490.
Article
86. Watad A, Quaresma M, Brown S, Cohen Tervaert JW, Rodríguez-Pint I, Cervera R, et al. 2017; Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome)-an update. Lupus. 26:675–81. DOI:
10.1177/0961203316686406. PMID:
28059022.
87. Hügle T, Bircher A, Walker UA. 2012; Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine. Rheumatology (Oxford). 51:761–2. DOI:
10.1093/rheumatology/ker388. PMID:
22157598.
88. Felicetti P, Trotta F, Bonetto C, Santuccio C, Brauchli Pernus Y, Burgner D, et al. 2016; Spontaneous reports of vasculitis as an adverse event following immunization: a descriptive analysis across three international databases. Vaccine. 34:6634–40. DOI:
10.1016/j.vaccine.2015.09.027. PMID:
26392009.
Article
89. Choi MJ, Kang SO, Oh JJ, Park SB, Kim MJ, Cheong HJ. 2018; Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea. Hum Vaccin Immunother. 14:1914–22. DOI:
10.1080/21645515.2018.1456602. PMID:
29953307. PMCID:
PMC6149703.
Article
90. Russell FM, Carapetis JR, Balloch A, Licciardi PV, Jenney AW, Tikoduadua L, et al. 2010; Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine. 28:3341–9. DOI:
10.1016/j.vaccine.2010.02.087. PMID:
20206670. PMCID:
PMC2854305.
Article
91. Tanaka E, Urata Y. 2012; Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-
α inhibitors. Hepatol Res. 42:333–9. DOI:
10.1111/j.1872-034X.2011.00937.x. PMID:
22150950.
93. Xuan D, Yu Y, Shao L, Wang J, Zhang W, Zou H. 2014; Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 33:577–86. DOI:
10.1007/s10067-013-2450-9. PMID:
24343455. PMCID:
PMC3962582.
Article
94. Chen MH, Chen MH, Liu CY, Tsai CY, Huang DF, Lin HY, et al. 2017; Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 215:566–73. DOI:
10.1093/infdis/jiw606. PMID:
28011918.
Article
95. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2016; 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 68:1–25. DOI:
10.1002/acr.22783. PMID:
26545825.
Article
96. The Korean Society of Infectious Diseases. 2012. Vaccination for adult. 2nd ed. MIP;Seoul:
97. Intongkam S, Samakarnthai P, Pakchotanon R, Narongroeknawin P, Assavatanabodee P, Chaiamnuay S. 2019; Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and/or biologics therapy. J Clin Rheumatol. 25:329–34. DOI:
10.1097/RHU.0000000000000877. PMID:
31764493.
Article
98. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. 2011; Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 70:1719–25. DOI:
10.1136/ard.2010.148783. PMID:
21719446.
Article
100. Elkayam O, Yaron M, Caspi D. 2002; Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 61:623–5. DOI:
10.1136/ard.61.7.623. PMID:
12079904. PMCID:
PMC1754139.
Article
101. Kim KA, Lee A, Ki M, Jeong SH. 2017; Nationwide seropositivity of hepatitis A in Republic of Korea from 2005 to 2014, before and after the outbreak peak in 2009. PLoS One. 12:e0170432. DOI:
10.1371/journal.pone.0170432. PMID:
28099530. PMCID:
PMC5242508.
Article
102. Askling HH, Rombo L, van Vollenhoven R, Hallén I, Thörner Å, Nordin M, et al. 2014; Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis. 12:134–42. DOI:
10.1016/j.tmaid.2014.01.005. PMID:
24529746.
Article
103. Lee YH, Choe JY, Park SH, Park YW, Lee SS, Kang YM, et al. 2010; Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J Korean Med Sci. 25:1431–7. DOI:
10.3346/jkms.2010.25.10.1431. PMID:
20890422. PMCID:
PMC2946651.
Article
104. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. 2004; Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 50:3619–25. DOI:
10.1002/art.20616. PMID:
15529372.
Article
105. Tam LS, Chan PK, Ho SC, Yu MM, Yim SF, Cheung TH, et al. 2010; Natural history of cervical papilloma virus infection in systemic lupus erythematosus-a prospective cohort study. J Rheumatol. 37:330–40. DOI:
10.3899/jrheum.090644. PMID:
20032093.
107. Mok CC, Ho LY, Fong LS, To CH. 2013; Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 72:659–64. DOI:
10.1136/annrheumdis-2012-201393. PMID:
22589375.
Article
108. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. 2009; Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 302:750–7. DOI:
10.1001/jama.2009.1201. PMID:
19690307.
Article
109. Nies K, Boyer R, Stevens R, Louie J. 1980; Anti-tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus. Comparison of the in vitro and in vivo responses. Arthritis Rheum. 23:1343–50. DOI:
10.1002/art.1780231203. PMID:
7006611.
110. Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. 2010; Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 62:64–74. DOI:
10.1002/art.25034. PMID:
20039397.
Article
111. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. 2007; Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther. 9:R38. DOI:
10.1186/ar2174. PMID:
17425783. PMCID:
PMC1906816.
Article
112. Abe T, Homma M. 1971; Immunological reactivity in patients with systemic lupus erythematosus. Humoral antibody and cellular immune responses. Acta Rheumatol Scand. 17:35–46. DOI:
10.3109/rhe1.1971.17.issue-1-4.06. PMID:
5546993.
Article
113. Devey ME, Bleasdale K, Isenberg DA. 1987; Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 68:562–9. PMID:
3652524. PMCID:
PMC1542762.
114. Kashef S, Ghazizadeh F, Derakhshan A, Farjadian S, Alyasin S. 2008; Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran J Immunol. 5:181–4. DOI:
IJIv5i3A7. PMID:
18791286.
115. Westra J, Rondaan C, van Assen S, Bijl M. 2015; Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 11:135–45. DOI:
10.1038/nrrheum.2014.206. PMID:
25486980.
Article
116. Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, et al. 2011; The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 13:R174. DOI:
10.1186/ar3497. PMID:
22024532. PMCID:
PMC3308109.
Article
117. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. 2012; Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 308:43–9. DOI:
10.1001/jama.2012.7304. PMID:
22760290. PMCID:
PMC3683869.
Article
118. Yun H, Xie F, Baddley JW, Winthrop K, Saag KG, Curtis JR. 2017; Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 44:1083–7. DOI:
10.3899/jrheum.160685. PMID:
28298565. PMCID:
PMC5724562.
Article
119. Guthridge JM, Cogman A, Merrill JT, Macwana S, Bean KM, Powe T, et al. 2013; Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 40:1875–80. DOI:
10.3899/jrheum.130170. PMID:
24037550. PMCID:
PMC3867792.
Article
120. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. 2018; Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 67:103–8. DOI:
10.15585/mmwr.mm6703a5. PMID:
29370152. PMCID:
PMC5812314.
Article
121. Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM, et al. 2014; Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 133:961–6. DOI:
10.1016/j.jaci.2013.11.043. PMID:
24582311. PMCID:
PMC4009347.
122. Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, et al. 2013; Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 309:2449–56. DOI:
10.1001/jama.2013.6768. PMID:
23780457.
123. Borte S, Liebert UG, Borte M, Sack U. 2009; Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford). 48:144–8. DOI:
10.1093/rheumatology/ken436. PMID:
19074187.
Article
124. Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Bühler S. 2017; Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation-a systematic review of randomized trials, observational studies and case reports. Vaccine. 35:1216–26. DOI:
10.1016/j.vaccine.2017.01.048. PMID:
28162821.